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The goal of gene therapy is to improve an affected indi-
vidual’s health by correcting a genetic defect. As has
been splashed across the news over the years, unfortunate
integration sites for the inserted genes have led to setbacks
in gene-therapy programs, for example, when they led to
leukemia in some treated individuals. Each viral vector
has a different integration profile, so researchers at the
San Raffaele Telethon Institute for Gene Therapy
optimized a lentiviral-based strategy with the hopes of
minimizing the risks of gene therapy. Two recent papers
from this institute indicate that their vectors do not lead
to aberrant clonal expansions in treated individuals—
meaning that it doesn’t look like they’ll cause cancer—
and that there were striking improvements in the affected
individuals, three of whom had the immunodeficiency
Wiskott-Aldrich syndrome and three of whom had meta-
chromatic leukodystrophy (MLD). What I found to be
most dramatic were the MLD-affected individuals, who
at 2–3 years of age all show normal language and cogni-
tive development. In contrast, their untreated older sib-
lings were severely affected at similar ages. Longer-term
monitoring is needed before the ultimate effect of gene
therapy is known, but both papers suggest that this
gene-therapy approach itself won’t initiate cancers and
that it might have a positive clinical impact for some
conditions.
Aiuti et al. (2013). Science. Published online July 11, 2013.
http://dx.doi.org/10.1126/science.1233151.
Biffi et al. (2013). Science. Published online July 11, 2013.
http://dx.doi.org/10.1126/science.1233158.
Large, Population-Based Cohort Yields Risk Estimates
for IVF
Across the world, millions of babies are born each year via
in vitro fertilization (IVF), and the vast majority of these
babies are healthy. Some research has suggested that IVF
increases the risk of certain congenital disorders, but others
have not, leaving this an open question. What has dogged
this field is the fact that it is difficult to collect thorough,
unbiased data on IVF, so even if an effect is detected, one
generally does not have the information to tell whether,
for example, the risk is caused by IVF itself or by the under-
lying condition that led to the IVF treatments. In what is
probably the biggest and most thorough study on this
topic to date, Sandin et al. took a population-based1Department of Human Genetics, Emory University School of Medicine, Atlan
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studies. Their study, which focused on autism and intellec-
tual disability, used a population-based Swedish birth
cohort of more than 2.5 million babies who could be
linked with patient and IVF registries. This allowed them
to monitor outcomes in an unbiased fashion because
they didn’t have to recruit subjects on the basis of a diag-
nosis or IVF procedure. Further reducing bias, each child
in Sweden receives a thorough developmental evaluation
at 4 years of age, and the children in the cohort were
followed for a mean of 10 years, so the research group’s
outcome information was about as complete as one could
hope. No increases in autism risk were found in conjunc-
tion with IVF, but compared to spontaneous conception,
IVF was associated with a small increase in risk of intellec-
tual disability. This increase was no longer present if the
authors considered only singleton births, so it could be
an indirect effect that could be minimized via single-em-
bryo transfer. The IVF-registry information enabled the
cohort to be stratified in several different ways on the basis
of various aspects of the IVF procedure. Therefore, Sandin
and colleagues could test the prevalent assumption that
intracytoplasmic sperm injection (ICSI) for IVF is riskier
than IVF without ICSI. In fact, they did find that risk of
autism and intellectual disability was slightly higher in
children conceived by ICSI than in those conceived via
other IVF procedures. What should be reassuring is that
no matter how they sliced up the cohort, the IVF-associ-
ated risks were pretty small.
Sandin et al. (2013). JAMA 310, 75–84.
This Looks Bad . . . or Does It?
The majority of reproductive-age women have uterine
fibroids, or leiomyomas. Although many of these benign
tumors of smooth muscle have detectable cytogenetic
rearrangements and tend to share mutations in common
genes, such as MED12 and FH, they have a very low risk
of developing into a malignancy. That is why it came as
such a surprise to Mehine et al. that they commonly found
chromothripsis in fibroids. These complex chromosomal
rearrangements that result from the shattering and
reassembly of chromosomes have only been recently docu-
mented in cancers and were thought to be a feature of
advanced cancer with a poor prognosis. Also contrasting
previous theories, chromothripsis in the fibroids occurred
in the absence of TP53 mutations. The number ofta, GA 30322, USA
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breakpoints present in chromosome rearrangements in the
fibroids tends to be lower than you see in cancer, but the
evidence of this process in benign tumors at all suggests
that we might need to rethink the role and mechanisms
of chromothripsis in oncogenesis; it might not always be
the harbinger of bad things.
Mehine et al. (2013). N. Engl. J. Med. 369, 43–53.
Could Diabetes Alter DNA?
As we age, the chance that our somatic cells will
accumulate mosaic chromosomal rearrangements in-
creases. This is a fairly new observation, and the causes
and consequences are not yet clear. Bonnefond et al.
were fascinated by this finding, and because they view
type 2 diabetes as a disease of accelerating aging, they
wondered whether diabetes might be associated with
this putative genetic marker of aging. Indeed, they were
more likely to find these mosaic chromosomal events
in type 2 diabetics, particularly those with vascular
complications. At this stage, their findings are only asso-
ciations, but the authors argue that the diabetic disease
process contributes to chromosome rearrangements.
Because other groups have found these rearrangements
to be more common in individuals with cancer, Bonne-196 The American Journal of Human Genetics 93, 195–196, August 8fond et al. also speculate that there are clinical implica-
tions when these rearrangements are found in affected
individuals.
Bonnefond et al. (2013). Nat. Genet. Published online July
14, 2013. http://dx.doi.org/10.1038/ng.2700.
Exercise Affects Your Jeans and Your Genes
Working out can change your health and your attitude, but
can it affect your DNA? Convinced by previous evidence
that an exercise program can influence DNA-methylation
patterns in skeletal muscle, Ro¨nn et al. wanted to find
out what happens in fat. In biopsies of adipose tissue,
they measured DNA methylation in healthy men at base-
line and after a 6-month exercise intervention. They found
modest but significant alterations to DNA-methylation
patterns, and these alterations often correlated with
changes in mRNA expression of neighboring genes. Some
of the genes with altered methylation patterns overlapped
candidate genes identified in genome-wide association
studies for type 2 diabetes or obesity. Many people start
exercising so they can fit into different jeans; perhaps
this increased activity also changes your genes and,
ultimately, your metabolism.
Ro¨nn et al. (2013). PLoS Genet. 9, e1003572.This Month in Our Sister JournalsCytosine-Modification Differences between
Populations
If a SNP confers a change in amino acid sequence, it is
straightforward to conceive the biological basis of a
genetic association with the SNP. When no such change
results, what then? Moen et al. were interested in the
role of cytosine modification as a contributor to complex
traits. Because European- and African-derived populations
have different rates of complex disease, the authors used
HapMap samples to explore differences in cytosine-
modification profiles between the two populations. Of
the thousands of CpG sites analyzed, 13% were differen-
tially modified between African and European samples.The cytosine-modification level at a significant number
of sites was influenced by SNP allele dosage, which pro-
vides another way that a SNP could influence disease;
the underlying DNA sequence could influence cytosine
modification, which, in turn, could influence gene expres-
sion. It seems pretty straightforward, but it’s not the whole
story; population identity itself is also a strong variable
when it comes to cytosine modification, arguing that
both gene-gene and gene-environment interactions
commonly influence the epigenetic differences between
populations.
Moen et al. (2013). Genetics. Published online June 21,
2013. http://dx.doi.org/10.1534/genetics.113.151381., 2013
